期刊文献+

重组人C1酯酶抑制剂中rcc-rhC1INH和ox-rhC1INH含量检测

Determination of rcc-rhC1INH and ox-rhC1INH in the recombinant human C1 esterase inhibitor
原文传递
导出
摘要 目的:分析重组人C1酯酶抑制剂(rhC1INH)中相关蛋白rcc-rhC1INH和ox-rhC1INH的含量。方法:采用反相高效液相色谱法进行测定,对该方法进行专属性、准确性和精密度检验,并用该方法对4批样品中的相关蛋白进行检测。结果:低浓度下,rhC1INH对照品、rcc-rhC1INH对照品和ox-rhC1INH对照品能够较好分离。rcc-rhC1INH和ox-rhC1INH 2种对照品质量浓度为0.2、1和1.4 mg·mL^(-1)时的回收率均在85%~115%的范围内。对同1批3个待测样品进行测定,rcc-rhC1INH含量为(0.082±0.008)%,RSD为9.8%;ox-rhC1INH含量为(0.35±0.05)%,RSD为14.3%,显示该方法具有较好的专属性、准确性和精密度。4批测试样品中,rcc-rhC1INH的含量分别为0.083%、0.021%、0.033%、0.042%,ox-rhC1INH的含量分别为0.34%、0、0、0。结论:经方法学验证,RP-HPLC方法可用于rhC1INH中rcc-rhC1INH和ox-rhC1INH的含量检测。 Objective:To analyze the contents of related proteins rcc-C1 INH and ox-C1 INH in the recombinant human C1 esterase inhibitor(rhC1 INH). Methods:The reversed phase high-performance liquid chromatography(RP-HPLC) was used to determine the relative proteins,the test was verified in specificity,accuracy and precision,and was used to detect the rcc-C1 INH and ox-C1 INH in 4 batches of samples. Results:RhC1 INH reference,rcc-rh C1 INH reference and ox-rhC1 INH reference could be well separated under the low concentrations.The recovery rates for the reference substances of rcc-C1 INH and ox-C1 INH at three concentrations(0.2,1 and 1.4 mg·mL-1) were all in the range of 85%~115%. Three groups from one batch were determined separately,the contents of rcc-C1 INH were(0.082±0.008)%,and the contents of ox-C1 INH were(0.35±0.05)%,with RSDs of 9.8% and 14.3%,respectively. This method showed good results in specificity,accuracy and precision. Four batches of rhC1 INH were determined,the contents of rcc-C1 INH were 0.083%,0.021%,0.033% and 0.042% for each,and ox-C1 INH were 0.34%,0,0,and 0,respectively. Conclusion:RP-HPLC can be used for the content determination of rcc-rhC1 INH and ox-rhC1 INH in rhC1 INH.
作者 秦玺 姚文荣 丁有学 史新昌 韩春梅 陶磊 李永红 饶春明 QIN Xi;YAO Wen-rong;DING You-xue;SHI Xin-chang;HAN Chun-mei;TAO Lei;LI Yong-hong;RAO Chun-ming(National Institutes for Food and Drug Control,Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,Beijing 100050,China)
出处 《药物分析杂志》 CAS CSCD 北大核心 2018年第11期1911-1916,共6页 Chinese Journal of Pharmaceutical Analysis
基金 药品医疗器械审评审批制度改革专项课题(ZG2017-3-02) 十三五科技重大专项课题"生物类似药质量相似性评价体系建设研究"(2015ZX09501008)
关键词 重组人C1酯酶抑制剂(rhC1INH) 反相高效液相色谱 rcc-rhC1INH ox-rhC1INH 含量检测 recombinant human C1 esterase inhibitor (rhC1INH) reversed phase high'performance liquidchromatography ( RP-HPLC ) rcc-C 1 INH ox-C 1 INI-I content detection
  • 相关文献

参考文献6

二级参考文献62

  • 1TAKATA T, OXFORD JT, BRANDON TR, et al. Deamidation al- ters the structure and decreases the stability of human lens betaA 3-crystallin [ J ]. Biochemistry, 2007,46 ( 30 ) : 8861.
  • 2HUANG L,LU J,Wroblewski VJ,et al. In vivo deamidation charac- terization of monoclanal antibody by LC/MS/MS [ J ]. Anal Chem,2005,77 (5) : 1432.
  • 3TAKATA T, WOODBURY LG, LAMPI KJ. Deamidation alters in- teractions of beta- erystallins in hetero- oligomers [ J ]. Mol Vis, 2009,15:241.
  • 4LIU YD, VAN Enk JZ, FLYNN GC. Human antibody Fc deamida- tion in vivo [ J ]. Biologicals, 2009,37 ( 5 ) : 313.
  • 5WRIGHT HT. Nonenzymatic deamidation of asparaginyl and glu- taminyl residues in proteins [ J ]. Crit Rev Biochem Mol Biol, 1991,26(1) :1.
  • 6CLARKE S. Aging as war between chemical and biochemical processes:protein methylation and the recognition of age-damaged proteins for repair[ J ]. Ageing Res Rev,2003,2 (3) :263.
  • 7ROBINSON NE,ROBINSON AB. Amide molecular clocks in dro- sophila proteins:potential regulators of aging and other processes [ J ] Mech Ageing Dev,2004,125 (4) :259.
  • 8REISSNER K J, ASWAD DW. Deamidation and isoaspartate for- matiorl in proteins: unwanted alterations or surreptitious signals [ J ]. Cell Mol Life Sei ,2003,60 (7) :1281.
  • 9SHIMIZU T, MATSUOKA Y, SHIRASAWA T. Biological signifi- cance of isoaspartate and its repair system[ J]. Biol Pharm Bull, 2005,28(9) :1590.
  • 10TREMOLADA G, LATTANZIO R, MAZZOLARi G, et al. The therapeutic potential of VEGF inhibition in diabetic microvascular complications [ J ]. Am J Cardiovase Drugs,2007,7 ( 6 ) : 393.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部